Multiplexed Endogenous Gene Activation-based Cancer Immunotherapy Development Service

Unleashing the Future of Cancer Immunotherapy through CRISPRa Precision

The immunotherapy approach employing multiplexed activation of endogenous genes by CRISPRa exhibits precision, multiplicity, safety, and the potential for significant antitumor immune responses, marking it as a promising and innovative strategy in the development of cancer Immunotherapy.

Depending on our extensive experience, Creative Biolabs excels in providing a service that implements a technical process directly activating endogenous genes through the CRISPRa system. This process induces a robust anti-tumor immune response, presenting an innovative and efficient approach in the realm of developing novel cancer immunotherapy.

Fig.1 Technical scheme of the development of multiplexed endogenous gene activation-based cancer immunotherapy.

Our technical process, by directly activating endogenous genes using the CRISPRa system, induces a potent anti-tumor immune response, providing an innovative and efficient approach for the development of new cancer immunotherapy.

Target Identification: Firstly, through an in-depth analysis of the tumor genome, target genes are identified. These genes are anticipated to enhance anti-tumor immune responses when activated.
CRISPRa: Utilizing CRISPRa technology, precise CRISPRa guide RNAs are designed and synthesized to target and activate the identified genes. Ensuring the high specificity of CRISPRa is crucial to prevent unnecessary gene activation.
Gene Delivery and Transfection: The designed CRISPRa system that guides RNAs, along with the CRISPR activation protein, are introduced into target tumor cells using a suitable vector. This can be achieved through viral vectors, nanoparticles, or other appropriate delivery tools.
Intracellular Activation: Within the tumor cells, the CRISPRa system recognizes and activates the target genes, leading to a significant increase in their expression levels. This further triggers the production and presentation of tumor antigens.
Antigen Presentation and Immune Response: The highly expressed tumor antigens are effectively presented to the immune system, eliciting a robust anti-tumor immune response. Activated immune cells, particularly T cells, are guided to attack and eliminate tumor cells.
Effect Evaluation: Comprehensive assessment of the new immunotherapy approach's efficacy and safety is conducted by monitoring factors such as the activity of immune cells and tumor size in models.

Advantages of Eliciting Antitumor Immunity Through Multiplexed Activation of Endogenous Genes

Precision Targeting	This method enables precise targeting of specific endogenous genes, ensuring a focused and tailored approach to activating the immune response against tumor cells.
Multiplexed Activation	The ability to activate multiple endogenous genes simultaneously enhances the presentation of tumor antigens, potentially broadening the spectrum of the immune response and improving its efficacy
Endogenous Gene Expression	By utilizing endogenous genes, the treatment leverages the natural cellular machinery, minimizing the introduction of exogenous elements. This may contribute to a more sustainable and regulated immune response.
Dramatic Antitumor Immune Responses	The approach has demonstrated the potential to induce robust and dramatic antitumor immune responses, suggesting its effectiveness in combating cancer.
Reduced Off-Target Effects:	Specific activation of endogenous genes reduces the likelihood of off-target effects, enhancing the safety profile of the immunotherapy and minimizing adverse reactions in non-tumor tissues.
Innovative CRISPRa Technology:	Leveraging CRISPR activation (CRISPRa) technology, this approach takes advantage of cutting-edge gene-editing tools, reflecting the forefront of innovation in biotechnology.
Potential for Personalized Treatment	The precise targeting of endogenous genes allows for a personalized approach, considering the unique genetic makeup of each patient's tumor for optimized therapeutic outcomes.

Publications Sharing

The observations in this literature indicate that the combined effect of synergistic activation and multiplexing can be attained through the utilization of CRISPR RNA (crRNA) arrays. Moreover, our findings reveal that crRNAs expressed towards the 5' end of 6-crRNA arrays exhibit enhanced activity. This not only signifies a more adaptable instrument for transcriptional modulation but also broadens our comprehension of the design possibilities and constraints associated with longer crRNA arrays for achieving multiplexed targeting.

Fig.2 Multiplexed activation of endogenous genes.¹

Our groundbreaking approach, activating endogenous genes through the CRISPRa system, pioneers a potent anti-tumor immune response. If you're inspired by progress and eager to revolutionize cancer immunotherapy, we invite you to contact us.

Reference

Bryson, James W., Jamie Y. Auxillos, and Susan J. Rosser. "Multiplexed activation in mammalian cells using a split-intein CRISPR/Cas12a based synthetic transcription factor." Nucleic Acids Research 50.1 (2022): 549-560.

For Research Use Only | Not For Clinical Use